Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -22.8 Million AUD | -0.2% |
| 2023 | -17.06 Million AUD | -87.54% |
| 2022 | -9.86 Million AUD | -18.65% |
| 2021 | -6.28 Million AUD | -32.26% |
| 2020 | -5.52 Million AUD | -56.94% |
| 2019 | -4.02 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -14.25 Million AUD | -52.99% |
| 2024 FY | - AUD | -28.71% |
| 2024 Q1 | -6.82 Million AUD | -12.37% |
| 2024 Q4 | -9.66 Million AUD | 0.0% |
| 2023 Q1 | -4.11 Million AUD | 47.11% |
| 2023 Q4 | -10.36 Million AUD | -86.36% |
| 2023 FY | - AUD | -87.54% |
| 2023 Q3 | -5.56 Million AUD | 32.37% |
| 2023 Q2 | -8.22 Million AUD | -99.93% |
| 2022 Q1 | -3.47 Million AUD | 27.99% |
| 2022 Q4 | -7.77 Million AUD | -80.56% |
| 2022 FY | - AUD | -18.65% |
| 2022 Q3 | -4.3 Million AUD | 38.08% |
| 2022 Q2 | -6.95 Million AUD | -100.27% |
| 2021 Q3 | -2.48 Million AUD | 29.48% |
| 2021 FY | - AUD | -32.26% |
| 2021 Q4 | -4.82 Million AUD | -93.71% |
| 2021 Q2 | -3.53 Million AUD | -100.0% |
| 2021 Q1 | -1.76 Million AUD | 0.0% |
| 2020 FY | - AUD | -56.94% |
| 2019 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Australian Clinical Labs Limited | 181.83 Million AUD | 112.544% |
| BCAL Diagnostics Limited | -5.66 Million AUD | -302.5% |
| Genetic Signatures Limited | -20.33 Million AUD | -12.149% |
| Genetic Technologies Limited | -11.43 Million AUD | -99.541% |
| Healius Limited | -298.09 Million AUD | 92.349% |
| Imagion Biosystems Limited | -13.69 Million AUD | -66.528% |
| Integral Diagnostics Limited | 12.33 Million AUD | 284.927% |
| INOVIQ Ltd | -6.63 Million AUD | -243.851% |
| Monash IVF Group Limited | 13.02 Million AUD | 275.117% |
| Rhythm Biosciences Limited | -6.79 Million AUD | -235.628% |
| Sonic Healthcare Limited | 1.65 Billion AUD | 101.375% |